德康醫療 (DXCM) 2008 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good day, everyone. Welcome to today's DexCom second quarter, year 2008 earnings conference call. Please be aware that today's conference is being recorded. At this time, I would like to turn the conference over to Mr. Terry Gregg. Please go ahead.

    各位大家好。歡迎參加 DexCom 2008 年第二季財報電話會議。請注意,今天的會議正在錄音。此時,我想將會議交給 Terry Gregg 先生。請開始。

  • - President, CEO

    - President, CEO

  • Thank you and welcome, today, to our third quarter investor conference call. Joining me today are Jess Roper, our Chief Financial Officer; and Steve Pacelli, our Senior Vice President for Corporate Affairs. I will ask Steve to lead it off by addressing the Safe Harbor requirements?

    謝謝並歡迎各位今天參加我們的第三季投資人電話會議。今天與我一同出席的有我們的財務長 Jess Roper,以及企業事務資深副總裁 Steve Pacelli。我會請 Steve 先開場,說明「安全港」(Safe Harbor) 相關要求,好嗎?

  • - SVP, Corporate Affairs

    - SVP, Corporate Affairs

  • Thanks, Terry. Some of the statements we will make in today's call may constitute forward-looking statements. These statements reflect management's expectations about future's events, operating plans and performance and speak only as of the date hereof. These forward-looking statements involve a number of risks and uncertainties. A list of the factors that could cause actual results to be materially different from those expressed or implied by any of these forward-looking statements is detailed under risk factors and elsewhere in our annual report on Form 10-K, our quarterly reports on Form 10-Q and our other reports filed with the SEC. We undertake no obligation to update publicly or revise these forward-looking statements for any reason. Terry.

    謝謝你,Terry。我們在今天電話會議中所做的部分陳述,可能構成前瞻性陳述。這些陳述反映管理階層對未來事件、營運計畫與績效的預期,且僅截至本日有效。此等前瞻性陳述涉及多項風險與不確定性。可能導致實際結果與任何前瞻性陳述所明示或暗示者有重大差異的因素清單,已於我們的 Form 10-K 年報、Form 10-Q 季報及其他向美國證券交易委員會(SEC)提交之報告中的「風險因素」及其他章節詳述。我們不承擔因任何原因公開更新或修訂此等前瞻性陳述之義務。Terry。

  • - President, CEO

    - President, CEO

  • Thanks, Steve. As always, we'll go through the financial review with Jess, we'll talk about the Edwards collaboration that we announced shortly before the start of this meeting, a commercial and reimbursement update, give a brief insight into our insulin pump partnership, a clinical and regulatory update followed by summary and conclusions and then we'll open it up for Q&A. Jess?

    謝謝你,Steve。照例,我們會先由 Jess 進行財務回顧,接著談談我們在本次會議開始前不久宣布的 Edwards 合作案、商業化與給付(reimbursement)最新進展,簡要說明我們的胰島素幫浦合作夥伴關係、臨床與法規更新,然後做總結與結論,最後開放問答。Jess?

  • - CFO

    - CFO

  • Thank you, Terry. DexCom reported product revenues of $1.9 million for the third quarter of 2008 compared to $1.2 million for the same quarter in 2007. An increase of 53%. Sequentially product revenues remained flat compared to the second quarter of 2008. During Q3, we sold approximately 770 SEVEN system starter kits. Sequentially, censor revenues were down 5% from Q2 and starter kit revenues were up 5% from Q2.

    謝謝你,Terry。DexCom 2008 年第三季產品營收為 190 萬美元,較 2007 年同季的 120 萬美元增加 53%。以季對季來看,產品營收與 2008 年第二季相比持平。第三季期間,我們約售出 770 套 SEVEN 系統入門套組。以季對季來看,感測器營收較第二季下降 5%,入門套組營收較第二季上升 5%。

  • Total revenue for the third quarter of 2008 was $1.9 million and included a small amount of development grant revenues associated with our joint development agreement with Animas Corporation, entered into during Q1. Cost of sales for the third quarter of 2008 totaled $3.8 million, compared to $3.1million for the same quarter in 2007. The increase was primarily due to higher sales volume and approximately $260,000 in developed cost of sales. The increase in product cost of sales relating to additional product sales was offset primarily by increased manufacturing absorption. Our gross margin loss for the third quarter of 2008 was $1.9 million, which remained flat as compared to the same quarter in 2007. Research and development expense increased by $1.7 million and totaled $5.4 million for the third quarter of 2008, compared to $3.7 million for the same quarter of 2007. Major elements of increased R&D expense included additional external development costs, facilities costs, and supply costs.

    2008 年第三季總營收為 190 萬美元,其中包含少量與我們在第一季與 Animas Corporation 簽訂之共同開發協議相關的開發補助收入。2008 年第三季銷貨成本合計 380 萬美元,較 2007 年同季的 310 萬美元增加。增加主要係因銷售量提高,以及約 26 萬美元的已開發(developed)銷貨成本。與額外產品銷售相關的產品銷貨成本增加,主要由製造吸收(manufacturing absorption)提升所抵銷。2008 年第三季毛利損失為 190 萬美元,與 2007 年同季持平。研發費用增加 170 萬美元,2008 年第三季合計 540 萬美元,較 2007 年同季的 370 萬美元增加。研發費用增加的主要項目包括額外的外部開發成本、設施成本與供應成本。

  • Sequentially, R&D costs increased by about $600,000, from Q2 due primarily to additional external development costs and lab supplies. As we continue with our in hospital efforts. Selling general and administrative expense totaled $6.7 million in Q3 of 2008 compared to $5.9 million in 2007. The increase was primarily due to increased general and administrative costs. Major components of increased SG&A expense included approximately $500,000 higher salaries, $200,000 in increased facilities costs, offset by $350,000 in lower sales commissions. Sequentially, SG&A expense decreased by about $600,000 from Q2 primarily due to lower commissions and share based compensation. Net interest expense totaled $700,000 for the quarter compared to net interest income of approximately $120,000 for the same quarter of 2007. The increase in net interest expense was primarily due to lower average balances of our cash and marketable securities combined with lower yields earned on those balances.

    以季對季來看,研發成本較第二季增加約 60 萬美元,主要因額外的外部開發成本與實驗室耗材,因我們持續推進院內(in hospital)相關工作。2008 年第三季銷售、一般及行政費用(SG&A)合計 670 萬美元,較 2007 年的 590 萬美元增加。增加主要係因一般及行政成本上升。SG&A 費用增加的主要構成包括薪資增加約 50 萬美元、設施成本增加 20 萬美元,並由銷售佣金減少 35 萬美元所抵銷。以季對季來看,SG&A 費用較第二季減少約 60 萬美元,主要因佣金與以股份為基礎之薪酬(share-based compensation)降低。該季淨利息費用為 70 萬美元,較 2007 年同季約 12 萬美元的淨利息收入增加。淨利息費用增加主要係因我們的現金與有價證券平均餘額較低,以及該等餘額所獲收益率下降。

  • Our net loss increased to $14.7 million for the third quarter of 2008, compared to $11.4 million during the same quarter in 2007. The net loss for the quarter included $2.7 million in noncash expenses centered primarily in share-based compensation. During the quarter, we invested about $610,000 in capital equipment and facilities to support our business. We ended the quarter with $30 million in cash, marketable securities and restricted cash and had working capital of $22 million. Cash, marketable securities and restricted cash decreased by $13 million during the quarter. Cash consumption during the quarter included our twice per year $1.5 million interest payment associated with our convertible debt. I would like to now turn it back to our President and CEO, Terry Gregg.

    2008 年第三季淨損增加至 1,470 萬美元,較 2007 年同季的 1,140 萬美元增加。該季淨損包含 270 萬美元的非現金費用,主要為以股份為基礎之薪酬。該季我們投入約 61 萬美元於資本設備與設施,以支援業務。我們在季末持有 3,000 萬美元的現金、有價證券及受限制現金(restricted cash),營運資金為 2,200 萬美元。該季現金、有價證券及受限制現金合計減少 1,300 萬美元。該季現金消耗包含我們每年兩次、與可轉換公司債相關的 150 萬美元利息支付。我現在把時間交回給我們的總裁暨執行長 Terry Gregg。

  • - President, CEO

    - President, CEO

  • Thanks, Jess. This afternoon we announced-- (audio difficulties).

    謝謝你,Jess。今天下午我們宣布——(音訊問題)。

  • Operator

    Operator

  • We have temporarily lost our host location. We would like to ask participants to remain connected as they rejoin. Again, we have lost our home location. Hold please.

    我們暫時失去主機端連線位置。請與會者保持連線,待其重新加入。再次說明,我們已失去主機端位置。請稍候。

  • - President, CEO

    - President, CEO

  • Operator, can you hear us. Thank you. Not sure where I cut you off, so let me just go back to the last area. We have previously discussed the growing clinical evidence that the close monitoring of glucose levels in critically ill patients, both with and without diabetes can positively impact the patient care and outcomes from a morbidity and mortality standpoint. We know that existing intermittent monitoring methods are not practical for hospitals to employ on a widespread basis. We believe that together with Edwards we will develop technology to allow clinicians to better maintain tight glycemic control of patients in an operating room or intensive care unit setting.

    接線員,你聽得到我們嗎?謝謝。不確定我講到哪裡中斷了,所以我回到上一段。我們先前已討論日益增加的臨床證據顯示,對重症患者(無論是否患有糖尿病)進行密切的葡萄糖監測,從罹病率與死亡率的角度來看,能對病患照護與結果產生正面影響。我們知道,現有的間歇式監測方法並不實際,醫院難以大規模採用。我們相信,與 Edwards 合作後,我們將開發出能讓臨床人員在手術室或加護病房環境中,更好地維持病患嚴格血糖控制(tight glycemic control)的技術。

  • We believe this collaboration will combine our continuous glucose sensing technology with Edwards leadership in the monitoring of critical ill patients and knowledge of the critical care environment. Under the terms of the agreement, Edwards will pay DexCom up to $36.5 million over the next three years in the form of licensing and development fees and regulatory milestones. Payments will include an initial upfront licensing and collaboration fee of $13 million. Additional research and development dollars of up to an additional $2.5 million paid during 2009 and the first half of 2010. Milestone payments of up to an additional $13 million, based on the achievement of certain regulatory approvals between 2009 and 2011. In addition, DexCom will receive either a profit sharing payment of 10%, or royalty of up to 6% of commercial sales.

    我們相信,此合作將結合我們的連續葡萄糖感測技術,以及 Edwards 在重症患者監測領域的領導地位與對重症照護環境的專業知識。依協議條款,Edwards 將在未來三年以授權費、開發費及法規里程碑款項的形式,支付 DexCom 最高達 3,650 萬美元。款項包含 1,300 萬美元的一次性前期授權與合作費。另有最高再增加 250 萬美元的研發款,於 2009 年及 2010 年上半年支付。里程碑款最高再增加 1,300 萬美元,取決於 2009 至 2011 年間取得特定法規核准的達成情況。此外,DexCom 將獲得商業銷售的 10% 利潤分成,或最高達 6% 的權利金(royalty)。

  • Edwards will be responsible for global sales and marketing, which is expected to begin in 2010, and DexCom will be responsible for initial manufacturing. Why Edwards Life Sciences? Edwards has been a world leader in critical care monitoring for more than 30 years, dating back to the development of the Swann Gansz line of hemodynamic monitoring devices for measuring heart pressure and output during surgical procedures and in ? postsurgical intensive care settings.

    Edwards 將負責全球銷售與行銷,預計於 2010 年開始;DexCom 將負責初期製造。為什麼選擇 Edwards Life Sciences?Edwards 在重症照護監測領域已領先全球超過 30 年,可追溯至其開發 Swann Gansz 系列血流動力學監測裝置,用於在手術過程中以及?術後加護病房環境中測量心臟壓力與輸出量。

  • Over of the years, Edwards has introduced a broad portfolio of critical care products, including advanced Venus access products, antimicrobial catheters, disposable pressure transducers, and a blood management protection system. In choosing Edwards as our partner for our in hospital continuous glucose monitoring systems, we evaluated a number of factors. During the development phase, we believe Edwards will bring a strong, technical team focused on continuous glucose monitoring in the critical care setting. We believe Edwards has a deep understanding and working relationship with clinicians in this setting on a worldwide basis. We also believe Edwards will bring a strong manufacturing team to help DexCom scale up and refine our manufacturing processes. As we move to commercialization, we believe Edwards' dedicated global salesforce and critical care is the best avenue to drive rapid market adoption of the in-house glucose sensing business.

    多年來,Edwards 推出多元的重症照護產品組合,包括先進的 Venus 血管通路產品、抗菌導管、一次性壓力傳感器(pressure transducers),以及血液管理保護系統。在為我們的院內連續葡萄糖監測系統選擇 Edwards 作為合作夥伴時,我們評估了多項因素。在開發階段,我們相信 Edwards 將帶來一支強大的技術團隊,專注於重症照護情境下的連續葡萄糖監測。我們相信 Edwards 對此情境下的臨床人員具有深厚理解並建立了全球性的合作關係。我們也相信 Edwards 將帶來強大的製造團隊,協助 DexCom 擴大產能並精進製造流程。隨著我們邁向商業化,我們相信 Edwards 專注且遍布全球的銷售團隊與其在重症照護領域的布局,是推動院內葡萄糖感測業務快速市場採用的最佳途徑。

  • Over the past several months of due diligence, it became increasingly clear to me and our team that the technical teams operate extremely well together and we expect this effort to jump start a new level of cooperation now that our formal agreement is in place.

    在過去幾個月的盡職調查過程中,我和我們的團隊愈來愈清楚地看到,雙方技術團隊的合作運作極為順暢;而在正式協議到位後,我們預期這項努力將啟動更高層次的合作。

  • As just reported, the third quarter of 2008 was flat in terms of our revenue and our new patient ads were down slightly from previous several quarters. This was not a surprise to us, and it is consistent with comments we made during our second quarter call, regarding the shift in our business from a cash pay basis to a broad reimbursement model. During Q3, we continued to see tremendous progress on the reimbursement front with the adoption of a number of new coverage policies for CGM and the establishment of contracts to cover our products, including key contracts with Blue Cross of California, and Aetna. We estimate that today in the United States there are over 100 million lives covered under CGM policies and expect that number to grow as we enter 2009. Yet these coverage policies and contracts have actually resulted in a short-term sales challenge.

    如同剛才所報告的,2008 年第三季就營收而言持平,而我們的新病患廣告投放量較前幾個季度略有下降。這對我們而言並不意外,且與我們在第二季電話會議中所提到的評論一致,即我們的業務正從自費(cash pay)模式轉向更廣泛的給付(reimbursement)模式。第三季期間,我們在給付面仍持續看到顯著進展,包含多項針對 CGM 的新承保政策獲得採用,以及建立涵蓋我們產品的合約,其中包括與加州藍十字(Blue Cross of California)及 Aetna 的關鍵合約。我們估計目前在美國已有超過 1 億人次(lives)在 CGM 政策下獲得保障,並預期隨著我們進入 2009 年,該數字將持續成長。然而,這些承保政策與合約在短期內實際上也帶來了銷售上的挑戰。

  • First, we are faced with a situation where patients and physicians are increasingly aware of our reimbursement progress and are now much more reluctant to initiate a cash purchase. As we have mentioned this is not atypical in medical device situations where reimbursement is becoming more prevalent but is not yet universal. Second, and more importantly, in spite of these positive coverage decisions, plans have made it administratively challenging for patients and their physicians to demonstrate medical necessity and ultimately receive reimbursement for CGM products.

    首先,我們面臨的情況是,病患與醫師對我們在給付方面的進展愈來愈了解,因此現在更不願意以自費方式啟動購買。正如我們先前提到的,在醫療器材領域中,當給付逐漸普及但尚未全面覆蓋時,這種情況並不罕見。其次,而且更重要的是,儘管有這些正面的承保決策,各保險計畫在行政流程上仍使病患及其醫師難以證明醫療必要性,並最終取得 CGM 產品的給付。

  • On average we are now required to collect five to six new documents per patient, and submit them as a package to the payer as part of the approval process. Required documentation can be as simple as an insurance card and an assignment of benefits form. But it can also include the previous two to four months of the patient's blood glucose logs, a letter of medical necessity prepared by the fiscal as opposed to a DexCom form letter and a copy of the physician's handwritten notes regarding a specific patient. And all of this must be done under the format of HIPAA compliance. Again this is not atypical in medical device situations where reimbursement is still developing.

    平均而言,我們現在必須為每位病患蒐集 5 到 6 份新的文件,並將其作為核准流程的一部分打包提交給付款方(payer)。所需文件可能簡單到只是一張保險卡與一份給付權益轉讓(assignment of benefits)表格;但也可能包括病患過去 2 到 4 個月的血糖紀錄、由財務端(fiscal)準備的醫療必要性說明信(而非 DexCom 的制式信函),以及醫師針對特定病患所寫的手寫病歷註記副本。而且所有這些都必須在符合 HIPAA 規範的格式下完成。再次強調,在給付仍在發展中的醫療器材情境裡,這並不罕見。

  • In spite of these new requirements the rate of new patients entering the system continues to increase. We believe patient demand for the SEVEN is real and is growing. Over the past several weeks we have seen the number of successful authorizations for insurance reimbursement increase. We believe that as the insurance companies gain experience in processing CGM claims they will gain a better understanding of what information is appropriate and necessary to make a coverage determination and ultimately we expect these administrative challenges to resolve themselves over the next several quarters.

    儘管有這些新要求,進入系統的新病患數量仍持續增加。我們相信市場對 SEVEN 的需求是真實存在且正在成長。過去幾週,我們看到成功取得保險給付核准(authorization)的件數增加。我們相信,隨著保險公司在處理 CGM 理賠(claims)方面累積經驗,他們將更了解哪些資訊適當且必要,以做出承保判定;最終我們預期這些行政上的挑戰將在未來幾個季度內逐步自行化解。

  • Nevertheless, in order to ensure DexCom has the staying power to overcome these short-term challenges, we have taken steps, effective immediately, to reduce our cash burn by approximately 15 to 20%, with the goal of reducing cash used in operations on a quarterly basis to approximately 11 million to $12 million of the second half of 2009. We are taking important steps today to improve our cash efficiency, optimize our internal return on investment and ultimately ensure we have the resources to compete as the CGM market more fully develops.

    然而,為了確保 DexCom 具備克服這些短期挑戰的續航力,我們已採取措施並即刻生效,將現金消耗(cash burn)降低約 15% 至 20%,目標是在 2009 年下半年把每季營運使用現金降至約 1,100 萬至 1,200 萬美元。我們今天採取重要步驟以提升現金使用效率、優化內部投資報酬,並最終確保我們在 CGM 市場更全面發展時具備競爭所需的資源。

  • Give you a quick update on our insulin pump partnership with Animas Corporation. We continue to make substantial progress on the joint development of an integrated insulin pump CGM system with Animas Corporation. Our continued goal is to complete all development, clinical and regulatory efforts with Animas and be positioned to launch our first product during the summer of 2009, but as you are well aware the timing of regulatory process is uncertain.

    簡要更新我們與 Animas Corporation 的胰島素幫浦合作夥伴關係。我們在與 Animas Corporation 共同開發整合式胰島素幫浦 CGM 系統方面持續取得重大進展。我們持續的目標是與 Animas 完成所有開發、臨床與法規相關工作,並在 2009 年夏季推出我們的第一項產品;但如各位所知,法規審查流程的時程具有不確定性。

  • We were extremely excited to see the study data presented by the Juvenile Diabetes Research Foundation at the 44th annual meeting of the European Association for the Study of Diabetes in Rome in September. For the first time, a truly independent study demonstrated that CGM is an effective tool to improve glucose control without increasing hypoglycemia, a common concern for patients employing intensive management. The 322 person, six month multi-center randomized trial included both pediatric and adult patients who used either insulin pumps or multiple daily injections to manage their diabetes.

    我們非常興奮地看到青少年糖尿病研究基金會(Juvenile Diabetes Research Foundation, JDRF)在 9 月於羅馬舉行的第 44 屆歐洲糖尿病研究協會(European Association for the Study of Diabetes, EASD)年會上發表的研究數據。這是首次由真正獨立的研究證實,CGM 是一項能改善血糖控制、且不會增加低血糖(hypoglycemia)的有效工具;低血糖是採用密集管理的病患常見的疑慮。這項 322 人、為期 6 個月的多中心隨機試驗納入兒科與成人病患,受試者使用胰島素幫浦或每日多次注射來管理其糖尿病。

  • Highlights from the data presented at EASD include the adult population meeting the primarily end point and achieving an A-1-C drop of 0.53%. The adult and pediatric population meeting their secondary end points with patients either reaching an A-1 C less than 7%, achieving an A-1-C reduction of greater than 10% from baseline or achieving an overall, absolute 0.5% reduction in A-1-C. Most importantly this improvement in control was observed without an increase in hypoglycemia, which is a common concern in intensively managed patients trying to achieve and improve glucose control.

    在 EASD 發表的數據重點包括:成人族群達成主要終點,A-1-C 下降 0.53%。成人與兒科族群達成次要終點,包括病患達到 A-1 C 低於 7%、A-1-C 較基線降低超過 10%,或整體 A-1-C 絕對值降低 0.5%。最重要的是,這種控制改善是在不增加低血糖的情況下觀察到的;低血糖是密集管理、試圖達成並改善血糖控制的病患常見的顧慮。

  • Finally, while there was no significance observed in patients age 15 to 25 due to low compliance, patients of all ages wearing sensors for six days or greater per week had an average A-1-C reduction of greater than 0.5%. As the only Company of an FDA approved 7-day censor, we believe we are uniquely positioned to help patients achieve better glucose control. We applaud JDRF for their continued support of outcome studies in the area of CGM technology and are extremely encouraged by the results.

    最後,雖然 15 至 25 歲病患因依從性(compliance)偏低而未觀察到顯著性,但所有年齡層中,每週配戴感測器達 6 天或以上的病患,其平均 A-1-C 降幅皆超過 0.5%。作為唯一擁有 FDA 核准 7 天感測器(censor)的公司,我們相信我們具備獨特優勢,能協助病患達成更佳的血糖控制。我們讚許 JDRF 持續支持 CGM 技術領域的結果研究(outcome studies),並對這些結果深受鼓舞。

  • In summary, CGM is here to stay. The data is clear. The independent study data presented by JDRF at the AESD meeting simply confirms the data presented in each of our peer reviewed published studies showing significant improvement in glucose control and outcomes. CGM is the first glucose monitoring technology to demonstrate both a reduction in hyper and hypoglycemia enabling more aggressive management of diabetes.

    總結而言,CGM 將會長期存在。數據已非常清楚。JDRF 在 AESD 會議上所呈現的獨立研究數據,只是再次確認我們每一項經同儕審查並已發表的研究所呈現的結果:血糖控制與臨床結局均有顯著改善。CGM 是第一項血糖監測技術,能同時證實可降低高血糖與低血糖,從而使糖尿病管理得以更積極。

  • The key thought leaders around the world in diabetes are saying CGM will be the standard of care in the next two to three years for a broad segment of the diabetes population. Today, we are renewing our commitment to the CGM category to patients and clinicians in both the hospital and in the ambulatory space and to growing an important and valuable business franchise. With our leadership role in CGM we must stay the course in building the category so that we will ultimately gain acceptance of our CGM products as the best standard of care for glucose management. Thank you. I'll now entertain questions.

    全球糖尿病領域的關鍵意見領袖(key thought leaders)都表示,未來兩到三年內,CGM 將成為廣大糖尿病族群的一項標準照護(standard of care)。今天,我們再次重申對 CGM 類別的承諾,面向醫院與門診(ambulatory)場域的病患與臨床人員,並致力於成長為一個重要且有價值的業務版圖。憑藉我們在 CGM 的領導地位,我們必須持續投入類別建構,最終讓我們的 CGM 產品被接受為血糖管理的最佳標準照護。謝謝。接下來我將回答問題。

  • Operator

    Operator

  • (OPERATOR INSTRUCTIONS) Our first question comes from Bill Plovanic with Canaccord Adams.

    (接線員指示)我們的第一個問題來自 Canaccord Adams 的 Bill Plovanic。

  • - Analyst

    - Analyst

  • I'm going to ask two questions, then I'll jump back into queue. My two questions are this. Number one, relative to the reimbursement you mentioned 100 million plus lives covered today. What is your thoughts on timing of getting north of 120 million, 130 million covered lives? Are you close? Is this going to be end of '09, relative to reimbursement? And the second question is, on your cash burn you mentioned, I didn't quite get if but you are reducing your cash burn by 15 to 20% in the second half of '09? Exactly what are you reducing it to? How are you doing that? It sounds like you are trying to stretch the money to last through to the end of '09. Those are my questions, thanks.

    我會問兩個問題,然後我會回到排隊序列。我的兩個問題如下。第一,關於你提到的給付,目前有超過 1 億人次(lives)受到保障。你對於何時能超過 1.2 億、1.3 億受保人次的時點有何看法?你們接近了嗎?就給付而言,會是在 2009 年底嗎?第二個問題是,關於你提到的現金消耗(cash burn),我沒有完全聽清楚:你們是在 2009 年下半年把現金消耗降低 15% 到 20% 嗎?具體要降到多少?你們要怎麼做到?聽起來你們是在努力把資金撐到 2009 年底。以上是我的問題,謝謝。

  • - President, CEO

    - President, CEO

  • Okay, Bill. Let me answer those in the order you asked. On the first one with regard to reimbursement I will preface it by saying it's always hard to look in a crystal ball and determine when a coverage decision will actually be issued. That said, if you remember in January of this year, I stood up at the JPMorgan conference and went out on a limb saying I we would have one national payer by the end of 2008 and we've got four of the national payers, waiting only on United. I can't speak for United, addressing this in the next 60 days. But we continue to make good progress, not only on coverage decisions, but in initiating contracts once the coverage decision has been published. So, I think it's continuing to grow. And I think ultimately, we will have not only all the national payers but most of the secondary and tertiary payers that oftentimes follow the national payers's lead.

    好的,Bill。我會依你提問的順序回答。第一個關於給付,我先說明:要像看水晶球一樣去判斷承保決策何時會真正發布,向來都很困難。話雖如此,如果你還記得今年 1 月,我在 JPMorgan 會議上曾大膽表示,我們會在 2008 年底前拿下一家全國性付款方(national payer);而目前我們已拿下四家全國性付款方,只剩 United 還在等待。我無法替 United 發言,是否會在接下來 60 天內處理此事。但我們持續取得良好進展,不僅在承保決策上,也在承保決策發布後啟動合約方面。因此,我認為覆蓋仍會持續成長。最終,我們不僅會涵蓋所有全國性付款方,也會涵蓋多數次級與三級付款方(secondary and tertiary payers),而這些付款方往往會跟隨全國性付款方的帶動。

  • With regards to cash burn, I think I'll take it from a top down look at it. As we went out, and looked at where we were spending our money, obviously we have historically been a very focused R&D Company that has commercial products. So we made a decision, having gone through a lot of diligence with the good folks at Edwards, to really focus on what was important. What's going to drive near term revenue for us. And although some of the R&D projects are exquisite and we clearly have the best technology out there, our product class now well beyond 7 days, and clearly has the top hypoglycemia awareness capability and detection, let alone the smallest footprint. But beyond that, there were other areas in which we decided to either postpone the development from the R&D standpoint or in some cases if necessary eliminate it all together.

    至於現金消耗,我想從較高層次的角度來看。當我們外出檢視資金花費去向時,很明顯我們歷來是一家高度聚焦研發、同時也有商業化產品的公司。因此,在與 Edwards 的優秀團隊進行大量盡職調查後,我們做出決定,要真正聚焦在重要事項上:哪些會驅動我們的近期營收。雖然部分研發專案非常出色,而且我們顯然擁有市場上最好的技術,我們的產品等級如今也早已超越 7 天,並且在低血糖警覺能力與偵測方面明顯居於領先,更不用說其最小的外形尺寸。但除此之外,還有其他領域我們決定要嘛從研發角度延後開發,要嘛在必要時乾脆完全取消。

  • The reason that I had to focus on saying less than $12 million, somewhere in the 10 million to $12 million per quarter by the second half, we have certain commitments that we have already made to our partners, and in filings we have already committed to the Food and Drug Administration. And we need to fulfill those. Those should be forthcoming in the first and second quarter of 2009, and then obviously we will commercialize those in some way but reduce some of that expenditure. The other side of it is, today, we reduced our head count effective this morning by some 10% in a number of different areas within the Company to again try to increase our runway.

    我之所以必須把重點放在「少於 1,200 萬美元」——也就是到下半年每季約 1,000 萬到 1,200 萬美元——是因為我們已經對合作夥伴做出了一些承諾,並且在申報文件中也已對美國食品藥物管理局(FDA)做出承諾。我們必須履行這些承諾。這些支出應會在 2009 年第一季與第二季陸續發生,之後我們顯然會以某種方式將其商業化,但會降低其中一部分支出。另一方面是,我們今天早上起已在公司內多個不同領域將人力編制削減約 10%,以再次嘗試延長我們的資金續航期。

  • - Analyst

    - Analyst

  • Okay. That's all I had. Thanks so much.

    好的。我就這些。非常感謝。

  • Operator

    Operator

  • Next we'll take a question from Ben Andrew with William Blair.

    接下來我們將接聽 William Blair 的 Ben Andrew 的提問。

  • - Analyst

    - Analyst

  • Good afternoon, Terry and Steve and Jess. Maybe talk a little bit about the Edwards transaction, and kind of how we should expect the cash to flow here. Is this the milestones? Or can you just identify those any more precisely for us? Or is that confidential in terms of the timing? And is the R&D likely to be spread evenly over the 18 months that you identified?

    各位下午好,Terry、Steve 和 Jess。能否談談 Edwards 這筆交易,以及我們應該如何預期現金在這裡的流向?這是里程碑款嗎?或者你們能否更精確地為我們辨識一下?還是說在時點上屬於機密?另外,你們所提到的 18 個月期間內,研發(R&D)是否可能平均分攤?

  • - President, CEO

    - President, CEO

  • I'm going to ask Steve to address this because he was the primary negotiator on our side of the equation.

    我請 Steve 來回答,因為他是我們這一方的主要談判代表。

  • - SVP, Corporate Affairs

    - SVP, Corporate Affairs

  • The way it breaks down it is effectively an up front payment for exclusivity then there are some R&D offset dollars that will basically flow on an amortized basis over a monthly basis throughout 2009 and into 2010. And there is no specific performance metric tied to those in the sense of those are not, I wouldn't call them milestone basis as long as the development is pushing forward, we are conning to make progress that money will just come in on a monthly basis. Then the milestone payments are tied specifically to regulatory approvals and without being specific there is some money specifically tied to a CE Mark approval and an FDA approval which would be some time in '09 would be the goal. Some money tied to a second generation product, the goal would be to get those approved in the '010 time frame.

    拆解來看,基本上是先支付一筆前期款以取得獨家權,接著會有一些研發費用抵減款,將在 2009 年全年度並延續到 2010 年,以按月攤銷的方式逐月流入。就某種意義而言,這些款項並沒有綁定特定的績效指標;也就是說,只要開發持續推進、我們持續取得進展,這筆錢就會按月進來,我不會把它稱作以里程碑為基礎。然後,里程碑款則是明確與法規核准掛鉤;在不具體說明的前提下,有一部分資金是與 CE Mark 核准以及 FDA 核准直接相關,目標是在 2009 年的某個時間點取得。另有一部分資金與第二代產品相關,目標是在 2010 年的時間框架內取得核准。

  • - Analyst

    - Analyst

  • That second generation would be integrated to Edwards system?

    那個第二代產品會整合到 Edwards 的系統中嗎?

  • - SVP, Corporate Affairs

    - SVP, Corporate Affairs

  • I haven't really seen any specifics on that yet.

    我目前還沒有看到任何相關的具體細節。

  • - Analyst

    - Analyst

  • Okay. Fine. Then, if you think about kind of the dollars of spending here for you, does that largely offset your expense for the in hospital product? Or are you still going to be absorbing a fair bit that have yourself?

    好的,了解。那麼,如果從你們的支出金額來看,這是否大致能抵銷你們在院內產品上的費用?還是你們仍需要自行吸收相當一部分?

  • - SVP, Corporate Affairs

    - SVP, Corporate Affairs

  • It completely absorbs the expense on the R&D side. Plus there's obviously the exclusivity portion, it covers -- we've got some responsibilities on the clinical and regulatory side. There is money in this, in these payments to offset those expenses as well.

    在研發端的費用是完全被吸收的。另外顯然還有獨家權的部分;我們在臨床與法規端也有一些責任。在這些付款中也包含用來抵銷那些費用的資金。

  • - Analyst

    - Analyst

  • Okay. And next will be R&D offsets we'll see R&D come down, is that right? Or it will be in the revenue side?

    好的。那接下來因為有研發抵減,你們的研發費用會下降,對嗎?還是會呈現在營收端?

  • - CFO

    - CFO

  • We haven't discussed that previously. But it's likely that the display will be similar to what we did with Animas and it will have development grant revenues offset by development cost of sales.

    我們之前沒有討論過這點。但很可能呈現方式會類似我們與 Animas 的作法,也就是以開發補助收入(development grant revenues)對沖開發成本銷貨成本(development cost of sales)。

  • - Analyst

    - Analyst

  • Okay.

    好的。

  • - CFO

    - CFO

  • And we'll finalize that of course in Q4.

    當然我們會在第四季把這件事定案。

  • - Analyst

    - Analyst

  • Sure, then Terry the cuts that you made in headcount, can you describe sort of where they were? And are there any particular projects or initiatives that might have generated revenue in the next couple of years that are impacted by that?

    當然。那麼 Terry,關於你們進行的人力削減,你能描述一下主要發生在哪些部門嗎?另外,有沒有任何可能在未來幾年帶來營收的特定專案或計畫因此受到影響?

  • - President, CEO

    - President, CEO

  • No the back answer, Ben, is there was nothing in those developmental progress or programs that would result in any revenue over the next couple of years. And that's why we either elected to postpone them or elected to eliminate them all together. I think one of the challenges of developing discipline as a Company, there are a lot of unique technologies that we were pursuing that were very interesting. I'm not sure that, given the value proposition, they were worth the expenditure of dollars. So the cuts obviously came a lot related to a reduction of those projects. There were some other just general, I think tightening of the belt type reductions. Also as we looked at our business, I would say that as also when you look at the SG&A, that we had increased, some of the back office situation that we are now challenged with, with regard to the reimbursement, we have had to address that. In many cases just with brute force. But other than that, it's just been a general, like I said, belt tightening on our part.

    不,簡短的回答是:Ben,那些開發進度或計畫在未來幾年都不會帶來任何營收。也因此我們要嘛選擇延後,要嘛選擇完全取消。我認為公司在建立紀律時的一個挑戰是,我們曾追求許多非常有趣的獨特技術;但我不確定在其價值主張之下,是否值得投入那些資金。因此,這次削減很大一部分與縮減那些專案有關。也有一些只是一般性的、我所謂勒緊褲帶式的削減。此外,當我們檢視業務時,我也會說,當你看 SG&A(銷售、一般及行政費用)時,我們曾增加了一些後勤/後台的配置;而現在在報銷(reimbursement)方面我們面臨挑戰,必須加以處理。在很多情況下只能用硬碰硬的方式。但除此之外,就如我所說,基本上就是我們在全面勒緊褲帶。

  • - Analyst

    - Analyst

  • Okay. If I can, one last question, talking about the pairs. How complicated is it to go through this logistical process with an individual patient and is it something that becomes routine very quickly for a payer? Or are there 250 local insurance payers that you have got to go through this process with every single one of them a couple of times before they routinize it. So is this national or is this really a local battle that required the brute force you talked about?

    好的。如果可以的話,最後一個問題,談到付款方(payers)。針對單一病患走完這套物流/行政流程有多複雜?對付款方而言,是否很快就能變成例行作業?還是說你們必須對 250 家地方保險付款方逐一走過這個流程,每一家都要來回幾次之後才會制度化?所以這是全國性的問題,還是其實是一場需要你所說的硬碰硬的地方性戰役?

  • - President, CEO

    - President, CEO

  • No it's national, unfortunately. I really wish it were local. But as we have looked at this, we have unfortunately been forced into the old pump model. Because that's what the payer system was kind of forcing us into. And so we have resisted as much as possible. We do need to streamline this. Brute force is only on a temporary basis. I would just say that we don't lack patience in the process.

    不幸的是,這是全國性的。我真希望它是地方性的。但我們檢視後發現,我們不幸被迫回到傳統的胰島素幫浦模式,因為付款方體系某種程度上在逼我們走那條路。所以我們已盡可能抵抗。我們確實需要把流程精簡化;硬碰硬只能是暫時的。我只能說,我們在這個過程中並不缺乏耐心。

  • We have, our salesforce has done an outstanding job of driving business in through the doors. We've not been able to adequately process those to get them reimbursed and patients in this economy have dramatically shifted from a cash pay to a reimbursement. If they think they've got any chance of getting reimbursement, they will postpone their decision. Used to be just swipe the credit card. Now we are asking patients in that scenario that they are looking at I would say $200 a month and in over a year period when they are also trying to put food on the table or gas in their tank, it's just been a real struggle because of the economy. Well, that has shifted over to the reimbursement. And this is just the collection itself. And then having to transmit that information over secure faxes for HIPAA compliance and if one document is not in that package or one T is not crossed appropriately, the letter of medical necessity or certificate of medical need does not meet a standard, and again you used the number 250, I'll say it's at least that, if not more, then we've got to collect that information and resubmit it. It is a paperwork log jam that we are working through as quickly as possible. But certainly and I give a lot of credit to our salesforce, we have more patients than we can possibly handle right now. That's been part of the problem.

    我們的銷售團隊在把業務帶進門方面做得非常出色。但我們沒能充分處理這些案件以取得報銷,且在這樣的經濟環境下,病患已大幅從自費轉向報銷。只要他們覺得有任何機會拿到報銷,就會延後決策。以前就是刷信用卡就好。現在在那種情境下,我們面對的是病患在考量——我會說每月 200 美元、而且是一年以上的期間——同時他們還要想辦法把食物放上餐桌或把油加進油箱,因為經濟因素真的很掙扎。於是就轉向報銷。而這還只是收款本身。接著還必須透過安全傳真傳送資訊以符合 HIPAA 規範;如果那個資料包裡少了一份文件,或某個細節沒有正確完成,醫療必要性函(letter of medical necessity)或醫療需求證明(certificate of medical need)就不符合標準。你剛剛提到 250,我會說至少是那個數字,甚至更多;然後我們就得再把資訊收集起來重新送件。這是一個我們正盡快疏通的文書塞車。但我也必須稱讚我們的銷售團隊:我們現在的病患量多到我們根本無法完全消化,這也是問題的一部分。

  • - Analyst

    - Analyst

  • Has the co-pay become a problem for any patients that you have heard about that might restrict uptake in this environment?

    在這樣的環境下,你們有聽說過自付額(co-pay)對任何病患造成問題、可能限制採用嗎?

  • - President, CEO

    - President, CEO

  • None whatsoever. The co-pay has been a blessing. I think we have had great coverage from that standpoint. I think it's just getting to that documentation and getting that prior authorization through the system has been the biggest barrier at this point.

    完全沒有。自付額反而是一大助力。就這點而言,我們的給付覆蓋做得很好。我認為目前最大的障礙是把文件準備齊全,並讓事前授權(prior authorization)順利通過系統。

  • - Analyst

    - Analyst

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Our next question from Tom Gunderson with Piper Jaffray.

    下一個問題來自 Piper Jaffray 的 Tom Gunderson。

  • - Analyst

    - Analyst

  • Hi, guys. Actually it's Amy Sullivan in for Tom today. First of all congratulations on the Edwards transaction.

    嗨,各位。其實今天是 Amy Sullivan 代替 Tom。首先恭喜你們完成 Edwards 這筆交易。

  • - President, CEO

    - President, CEO

  • Thanks, Amy.

    謝謝你,Amy。

  • - Analyst

    - Analyst

  • Couple of quick housekeeping things. At the beginning of the call you mentioned censor revenues down, was that 5% or 7%? I missed that.

    幾個快速的例行確認事項。你們在電話會議一開始提到感測器(censor)營收下滑,那是 5% 還是 7%?我漏聽了。

  • - President, CEO

    - President, CEO

  • That was 5%, Amy.

    是 5%,Amy。

  • - Analyst

    - Analyst

  • Okay. Then did you give a dollar amount as far as the total milestone payments with Edwards?

    好的。那你們有提供 Edwards 的里程碑付款總額的金額嗎?

  • - President, CEO

    - President, CEO

  • On the hospital side?

    是指院內端嗎?

  • - Analyst

    - Analyst

  • Correct.

    對。

  • - President, CEO

    - President, CEO

  • Yes. Up to $13 million.

    有的。最高可達 1,300 萬美元。

  • - Analyst

    - Analyst

  • Okay. And then you talk about the being on track as far as the time line with the Animas combination there. Does that mean that you are looking to submit still here before year end?

    好的。然後你們提到 Animas 的組合在時程上仍按計畫進行。這是否表示你們仍打算在年底前提交申請?

  • - President, CEO

    - President, CEO

  • We, I think we are going through that process right now with Animas and in fact, I'll be chatting with them to get an update this week, to be sure. But as far as we can tell at this point, all systems are go. We have a human use requirement. We've engaged, that's on track at this point and active. So unless there is something that we are not aware of, by either Company at this point, again I always want to hesitate, because this is a brand new product. But as far as we can tell, we are on track.

    我們——我想我們現在正與 Animas 一起走那個流程。事實上,我這週會和他們通話以取得最新進度、確認無誤。就我們目前所能判斷,一切系統都準備就緒。我們有一個人體使用(human use)的要求;我們已經啟動相關作業,目前進度如期且正在進行中。所以除非目前任一家公司有我們尚未察覺的狀況——我總是會想保留一些空間,因為這是全新的產品——但就目前所見,我們仍在軌道上。

  • - Analyst

    - Analyst

  • Okay. Then just two final ones. If you can give us an update as far as where things are at, with your work on getting CE Mark. Then I'm also curious as far as how your conversations with payers may have changed with all the new data that was released in Rome in September.

    好的。那最後兩個問題。如果可以的話,請您更新一下目前取得 CE Mark 的進度。另外我也想了解,隨著 9 月在羅馬公布的新數據,你們與付款方(payers)的對話是否有所改變。

  • - President, CEO

    - President, CEO

  • Well, CE Mark we have gone through our ISO audit, we have been informed by our notified body that they are recommending both certificate for ISO compliance and certification and simultaneously, CE Mark authorization. And so I would expect, I think we have given Q4 as our date previously. And we are holding to that date as we speak. The other question you had Amy? I'm sorry.

    關於 CE Mark,我們已完成 ISO 稽核;我們已收到通知機構告知,他們建議核發 ISO 符合性與認證證書,同時也建議核准 CE Mark 授權。因此我預期——我們先前給的時程是第 4 季,我們目前仍維持這個時程。你另一個問題是什麼,Amy?抱歉。

  • - Analyst

    - Analyst

  • Just with regards to the data that was presented in Rome?

    就是關於在羅馬發表的數據?

  • - President, CEO

    - President, CEO

  • On the payer, yes. It's just been part of this compendium of data information that we have continued to submit as things get published. We add to our packet of information. I think it's -- the goal now is for them to digest it, them being the payer system. And our goal is to demonstrate to them that if you look at the entry criteria for this population, they were actually relatively well controlled, they had an average A-1-C upon entry of 7.6% and clearly demonstrating a reduction of 0.5 in that. Plus if you look at secondary end points being met even more dramatically if they used the products six days or more. That information is going back to all the payers. Right now, as you well know, most of the coverage decisions are relatively limited to something about hypoglycemia, recurring hypoglycemia, hypoglycemia unawareness. We don't think those coverage decisions should be as restrictive. This data certainly clearly demonstrates that I think, along with the JDRF and a campaign, public relations campaign going back to all of the payer systems to expand those indications for use. That's where we're at, at this point.

    關於付款方,是的。這些數據只是我們持續提交、並隨著研究發表而不斷補充的一整套資料彙編的一部分;每有新發表,我們就把它加入我們的資料包。我想——目前的目標是讓他們消化這些內容,「他們」指的是付款方體系。我們的目標是向他們證明:如果你看這個族群的入組標準,他們其實控制得相對不錯,入組時平均 A1C 為 7.6%,而且清楚顯示 A1C 降低了 0.5。此外,如果看次要終點,在每週使用產品達 6 天或以上時,達成情況更為顯著。這些資訊都已回傳給所有付款方。就如你所知,目前大多數的給付決策相對侷限,主要聚焦在低血糖、反覆低血糖、低血糖無感知等。我們認為這些給付決策不應如此嚴苛限制。這些數據非常清楚地證明——我想,配合 JDRF 以及一項公關宣導活動——我們會回到所有付款方體系,推動擴大這些使用適應症。這就是我們目前的進度。

  • - Analyst

    - Analyst

  • Okay. Thank you.

    好的。謝謝。

  • Operator

    Operator

  • Next we hear from Mimi Pham with JMP Securities.

    下一位提問者是來自 JMP Securities 的 Mimi Pham。

  • - Analyst

    - Analyst

  • Hi. Good evening. In terms of the Edwards product, would you be receiving any minimum payments or royalties if for some reason commercialization is delayed beyond 2010?

    嗨,晚安。就 Edwards 的產品而言,如果因某些原因商業化延後到 2010 年之後,你們是否會收到任何最低付款或權利金?

  • - President, CEO

    - President, CEO

  • Without getting into specifics, maybe the royalty and profit sharing is based solely on the commercial launch. So the answer in that respect would be no. The, again we have divided this up. There is an up front element. There is a kind of an R&D offset payment, probably not using the right term from an accounting perspective. But they are funding on a monthly basis as I discussed to account for R&D expenditures and there are milestone payments based on regulatory approvals. There, if for some reason the approval was delayed, those payments would not be payable until we received the approval. So if that answers your question, then yes. If there's a delayed approval, there is some portion of the milestone payment that would be at risk for a delay or reduction, depending on the nature of the delay.

    在不談具體細節的前提下,權利金與利潤分成是完全以商業上市為基礎。因此就這點而言,答案是否定的。另外,我們把這件事拆成幾個部分:有一筆前期款;有一種研發費用抵扣款(從會計角度來說我可能用詞不精準);他們會如我所說按月提供資金以反映研發支出;此外還有以法規核准為基礎的里程碑款。如果因某些原因核准延遲,這些款項在我們取得核准之前都不需要支付。所以如果這回答了你的問題,那就是:是的,若核准延遲,部分里程碑款可能會面臨延後或減少的風險,取決於延遲的性質。

  • - Analyst

    - Analyst

  • Okay. And then in terms of either 10% of the profit share or 10% of royalty, is that of the price of just the stand alone system? Like if it is integrated into some other system or product how does that work out?

    好的。那麼就利潤分成 10% 或權利金 10% 而言,這是以單獨系統的價格為基礎嗎?如果它整合到其他系統或產品中,會怎麼計算?

  • - President, CEO

    - President, CEO

  • It's based on the disposable censor component of the system.

    是以系統中的一次性(拋棄式)感測器元件為基礎。

  • - Analyst

    - Analyst

  • Just the disposable component?

    只針對一次性元件?

  • - President, CEO

    - President, CEO

  • Yes.

    是的。

  • - Analyst

    - Analyst

  • Then you mentioned just being responsible for the initial manufacturing. Is that something where you would potentially convert the manufacturing to Edwards? All of it?

    你提到你們只負責初期製造。那是否可能把製造轉移給 Edwards?全部都轉移嗎?

  • - President, CEO

    - President, CEO

  • I'd tell you it's our present intent to continue to manufacture sensors. Edwards has some rights under the contract to take over manufacturing at a future date which is where it would shift from a profit sharing world to a royalty world if and when that shift for manufacturing occurred but I would tell you it is our present intention and I believe Edwards as well would prefer to have us manufacturing the disposables.

    我可以說,我們目前的意圖是持續製造感測器。依合約,Edwards 在未來某個時間點有權接手製造;一旦製造發生轉移,利潤分成模式就會轉為權利金模式(若且當該製造轉移發生時)。但我會說,我們目前的意圖——我相信 Edwards 也一樣——是希望由我們來製造這些一次性耗材。

  • - Analyst

    - Analyst

  • Then a couple questions on the (inaudible) side. Can you give us an idea just generally of customer retention? In terms of the patients on the SEVEN?

    接著有幾個關於(聽不清)那邊的問題。你能否大致說明一下客戶留存率?就使用 SEVEN 的病患而言。

  • - President, CEO

    - President, CEO

  • Yes. We have never publicly disclosed that data and we are not inclined to for competitive reasons, more than anything, MiMi.

    可以。我們從未公開披露過那項數據,且基於競爭因素——最主要是這個原因——我們也不傾向披露,MiMi。

  • - Analyst

    - Analyst

  • Okay. Okay. Thank you very much.

    好的。好的。非常感謝。

  • - President, CEO

    - President, CEO

  • Thanks.

    謝謝。

  • Operator

    Operator

  • We'll take our next question from Sara Michelmore, Cowen & Co.

    下一個問題來自 Cowen & Co. 的 Sara Michelmore。

  • - Analyst

    - Analyst

  • Terry, I'm interested in getting your thoughts on the JDRF data that was presented back in September, in terms of the compliance factor in that data set there were some age groupings that did better than others, which was attributed to some differences in compliance. Just wondering what your thoughts are there, in terms of the impact of the device in certain age groups, particularly juveniles. And what, if anything, does that mean in terms of device design going forward?

    Terry,我想聽聽你對 9 月發表的 JDRF 數據的看法。就依從性(compliance)因素而言,在那組數據中有些年齡分組表現比其他組更好,這被歸因於依從性差異。想請問你怎麼看:裝置在某些年齡層、特別是青少年(juveniles)中的影響?以及若有的話,這對未來裝置設計意味著什麼?

  • - President, CEO

    - President, CEO

  • Well, certainly when you looked at the what I'll call the adolescent group, I think Bill Tamberlin from Yale summed it up perfectly by saying why teenagers didn't have diabetes and they were noncompliant as well. I think that's part of the, this image issue that teenagers go through. They want a much greater degree of privacy, and that is part of the psychological challenge. I don't think it's a product design issue, if you look at the pediatric group, obviously a lot of parents are insisting on that. The design is more than adequate. Again, I wouldn't say that there's any requirement for a design change.

    嗯,當你看我稱之為青少年族群時,我認為耶魯的 Bill Tamberlin 總結得很到位:為什麼青少年不只是有糖尿病,他們也同樣不依從。我想這是青少年會經歷的一部分形象問題。他們想要更高程度的隱私,這也是心理層面的挑戰之一。我不認為這是產品設計問題;如果看兒科族群,顯然很多家長會堅持使用。設計已經綽綽有餘。同樣地,我不會說需要做任何設計變更。

  • Patients basically from our perspective, we make it very convenient. If you look at the utilization of six days or greater to have the highest degree of results, all the other competitors have to change it at least once if not twice during that time frame. We don't. So we, in fact, a little interesting anecdote is, we have previously said that once reimbursement was in place, we felt that that would reduce the reliance on patients using the product beyond 7 days. And I think now looking at some of the data we look at, that may be wrong and has nothing to do with the cost, it has really to do with the convenience of not having to exchange it out at any time frame. We know they routinely use it more than 10 days and I think, given the economy, they are probably stretching it even more than that. And we certainly routinely here have used beyond two weeks a single censor.

    就病患而言,從我們的角度,我們讓使用非常便利。如果你看使用達 6 天或以上時能得到最高程度的效果,而所有其他競爭對手在那段期間至少要更換一次、甚至兩次;我們不需要。所以有個有趣的小插曲是:我們之前曾說,一旦給付到位,我們覺得這會降低病患把產品使用超過 7 天的依賴。我想現在從我們看到的一些數據來看,這可能是錯的,而且與成本無關,真正原因是便利性——在任何時間點都不必更換。我們知道他們經常使用超過 10 天;而且考量經濟狀況,他們可能拉得更久。我們這裡也確實經常把單一感測器使用超過兩週。

  • But the data, I think was just so powerful. There was a lot of speculation relative to the design of the trial, reflecting back on the STAR ONE trial that probably failed because of lack of adequate compliance, not because of technology. From that standpoint or even protocol design if you really kind of carve out some of the noncompliance issues even in the STAR ONE trial, it is highly statistically effective. But from our standpoint, I'm very comfortable with the way that the trial was run and the fact that, again, remember, a 7.6 starting A-1-C s a lot harder to get down to a 0.53% reduction than if they were starting at 8.5. So I think the data itself was overwhelmingly positive.

    但我認為那份數據非常有力。外界對試驗設計有很多揣測,回頭看 STAR ONE 試驗,可能失敗是因為依從性不足,而不是技術問題。從那個角度,甚至就方案設計而言,如果你真的把 STAR ONE 試驗中的一些不依從問題剔除,它其實具有高度統計顯著的效果。但就我們而言,我對試驗的執行方式非常放心;而且再次提醒,起始 A1C 為 7.6% 要降到 0.53% 的降幅,比起起始 8.5% 要困難得多。所以我認為這些數據整體上是壓倒性地正面。

  • - Analyst

    - Analyst

  • Okay. And you started to answer my second question which was related to censor frequency. And if you had to sort of pick an average, I understand there are people that do use it for extended use. What is your best guess in terms of the length of time that folks are using the censors? Are people using the censor intermittently in your view? Are they actually using it continuously? Thanks.

    好的。你也開始回答我的第二個問題,與感測器更換頻率有關。如果要你選一個平均值——我知道有人會延長使用——你對大家使用感測器的時間長度最佳猜測是什麼?你認為人們是間歇性使用感測器嗎?還是其實是持續使用?謝謝。

  • - President, CEO

    - President, CEO

  • That's a good question. I think that patients are using it longer than ever before. And we routinely hear of it more than ten days. If they can get it out to two weeks, they will. I think you have, where we begin to see stretch use is obviously just analyzing from a cash pay group versus a reimbursement group, they may be using it a bit longer. But I don't see, it's hard to tell if it's intermittent use. If somebody is using two a month, is that one a week intermittent use? Or is that 100%, 14 days at a time? We don't have the optics on that standpoint. But in terms of average utilization, we haven't seen a change in that, in the last two to three months.

    這是個好問題。我認為病患使用的時間比以往更長。我們經常聽到超過 10 天;如果能撐到兩週,他們就會。我想我們開始看到延長使用的情況,顯然是從自費族群相對於有給付族群的分析來看,自費者可能會用得更久一些。但我看不出——很難判斷是否為間歇性使用。如果有人一個月用兩個,那是一週用一個的間歇性使用?還是每次連續用 14 天、等於 100% 使用?我們在這方面沒有足夠的可視性。不過就平均使用量而言,過去兩到三個月我們沒有看到變化。

  • - Analyst

    - Analyst

  • Okay. And any change in terms of dealing with the physicians and their receptiveness to the product? We talked a little bit about patients and insurers. Any changes going on, on the physician side in terms of acceptance and the technology interest in kind of going through the hassle of dealing with the paperwork, et cetera?

    好的。那麼在與醫師互動以及他們對產品的接受度方面,有沒有任何變化?我們稍微談到病患與保險公司。那在醫師端,就接受度以及對技術的興趣(是否願意花力氣處理文書作業等等)方面,有沒有任何變化?

  • - President, CEO

    - President, CEO

  • We have seen a dramatic uptick in physicians wanting to use it. I think once you got your key opinion leaders moving from only the most intensively managed patients to publicly stating all patients with diabetes should be using this, it's a standard of care in the next two to three years, that migrates down into the decile list of insulin prescribers and we are beginning to get more and more requests for information, more and more requests for training and education at the physician level. There is no, there is absolutely no lack of patient, I really wish and I'm not going to disclose the number, because the folks here won't let me. But I will just suggest to you that our funnel is full. Our salesforce has done an outstanding job. We have failed them from internal processing. The insurance companies have failed them from internal processing. But not the physicians prescribing or the patients wanting. We do not lack for demand. It's the ability to process this in a timely fashion that is our number one priority.

    我們看到醫師想要使用的意願大幅上升。我認為一旦關鍵意見領袖從只針對管理最密集的病患,轉而公開表示所有糖尿病患者都應該使用這個,並且在未來兩到三年會成為照護標準,這樣的觀點就會往下滲透到胰島素處方醫師的前十分位名單中;我們也開始在醫師層級收到越來越多資訊需求、越來越多訓練與教育的要求。病患完全不缺,我真的希望——我不會揭露數字,因為在場的人不讓我說——但我只能跟你暗示,我們的漏斗是滿的。我們的業務團隊做得非常出色。我們在內部處理流程上辜負了他們。保險公司在內部處理流程上也辜負了他們。但不是醫師不開立處方,也不是病患不想要。我們不缺需求;我們的第一優先事項是能否及時處理這些案件。

  • - Analyst

    - Analyst

  • Okay what loosens up the log jam, Terry? What time frame can we hope that things get cleared up a little bit here?

    好的,Terry,什麼能讓這個塞車狀況鬆動?我們大概什麼時間框架可以期待事情稍微理順一些?

  • - President, CEO

    - President, CEO

  • Well, what loosens up the log jam is just processing, more and more processing. Just brute forcing those files to go and be received by a claims adjuster. And I think it's going to resolve itself over the next several quarters as I mentioned earlier. It's just, it's not, if it's going to happen, it's when it's going to happen. Again, I can't tell you more distinctly than several quarters. We have, over the past, probably six weeks, saw dramatic improvement in terms of processing. Some of that is us by throwing more resources at it, some of that is the system opening up a bit as insurance companies get a bit more comfortable with the whole process.

    嗯,讓塞車鬆動的就是處理量——更多、更多的處理。就是用最直接的方式把那些檔案推進去,讓理賠審核人員能收到。我認為正如我先前提到的,接下來幾個季度會自行逐步解決。這不是會不會發生的問題,而是什麼時候發生的問題。同樣地,我無法比「幾個季度」說得更精確。過去大概六週,我們在處理速度上看到顯著改善;一部分是我們投入更多資源,另一部分是隨著保險公司對整個流程更熟悉,系統也稍微順暢了一些。

  • - Analyst

    - Analyst

  • Great, thank you.

    很好,謝謝。

  • Operator

    Operator

  • (OPERATOR INSTRUCTIONS) Next we hear from [Shawn Pitts], with Stephens, Inc.

    (接線員指示)下一位是來自 Stephens, Inc. 的 [Shawn Pitts]。

  • - Analyst

    - Analyst

  • Terry, just as you draw on your experiences, managing through a similar reimbursement cycle on the pump side is there anything unique you are seeing in terms of the administrative difficulties that you all are having to process through on the CGM side?

    Terry,就你過去在幫浦端管理類似的給付循環的經驗來看,在 CGM 端你們目前必須處理的行政作業困難,有沒有看到任何特別或不同之處?

  • - President, CEO

    - President, CEO

  • Not more difficult, actually less difficult. I see everything faster, Shawn. And I think the real reason, back in the old pump war days, utilization relative to pumps was not directly, at the time before reimbursement was not as closely connected to the benefits of A-1-C improvement. Today nobody disputes that. That was really, I think once pumps got reimbursed, it was based on that you had a tool in which you could lower A-1-C. There is nobody that doubts that improved A-1-C is better. I think now we are entering into a new paradigm where A-1-C is a surrogate marker but it's probably not the best surrogate marker because if you look at multiple patients with similar A-1-Cs or glycemic variability, profiles are much much different one will be 80 to 150 and another will be 40 to 400. The value of that photoglycemic exposure is now coming into play but that is still at the scientific level and a key thought leader level of what to do about that but clearly reducing A-1-C.

    其實沒有更困難,反而更容易。我覺得一切都更快,Shawn。我認為真正的原因是,在早期的「幫浦戰」年代,在給付尚未到位之前,幫浦的使用與 A1C 改善的效益之間,當時並沒有那麼直接、那麼緊密的連結。今天沒有人質疑這點。我想幫浦一旦獲得給付,主要就是基於你有一個工具可以降低 A1C。沒有人懷疑 A1C 改善是更好的。現在我認為我們正進入一個新的典範:A1C 是一個替代指標,但它可能不是最好的替代指標,因為你看多位 A1C 類似的病患,他們的血糖變異度(glycemic variability)輪廓可能差很多;一個可能在 80 到 150,另一個可能在 40 到 400。這種血糖暴露的價值現在開始被納入考量,但這仍停留在科學層面與關鍵思想領袖層面,大家在討論該如何處理;但很明顯,降低 A1C——

  • So everything, again I remind everyone that in January we went out on a limb to say we thought one national payer would issue a coverage decision and quite frankly, we would be from a financial standpoint as a Company, probably if the economy hadn't taken a downturn, we would probably be in better shape in terms of a revenue number because we would still be more skewed towards cash pay. This caught us all by surprise. I never thought when I stood up in January that we would have all these coverage decisions and contracts in place and then be forced into a decision of data accumulation, manipulation and submission that we are bogged down with today.

    所以,再次提醒大家,一月時我們曾大膽預測,認為會有一家全國性付款方做出給付決策;坦白說,從公司財務角度,如果經濟沒有下滑,我們的營收數字可能會更好,因為我們仍會更偏向自費。這件事讓我們所有人都措手不及。我從沒想到我在一月站上台時,我們會有這麼多給付決策與合約到位,然後卻被迫進入資料累積、處理與提交的決策,結果就像今天這樣被卡住。

  • - Analyst

    - Analyst

  • Terry, as we look for way points in terms of adoption curve on CGM there is nothing that you are seeing right now that would make you think that that curve would be any lower or less of a slope than what you saw on the pump side of the world?

    Terry,當我們在尋找 CGM 採用曲線的里程碑時,你現在看到的情況,有沒有任何跡象會讓你覺得那條曲線會比你在幫浦端看到的更低、或斜率更小?

  • - President, CEO

    - President, CEO

  • No. No. Far, it's actually going to be steeper. I think if you look out even next year with sensor integrated pump with Animas that's going to drive adoption as well, because that's, that's the lowest of the low hanging fruit, in terms of that intensively managed population. Plus right now, I have said historically, about 50/50 pump versus MDI use. My guess is, today it's probably 60% pump use in our population, 40% MDI So clearly, I don't see any, anything other than a steeper adoption curve as we go forward and more information is even presented from that standpoint.

    沒有。沒有。反而會更陡。我認為如果你看明年,與 Animas 的感測器整合幫浦也會帶動採用,因為那是最容易摘取的果實——就那群密集管理的人口而言。另外,我過去一直說大約是 50/50:幫浦使用 vs. MDI(多次每日注射)。我猜今天在我們的人群中可能是 60% 使用幫浦、40% 使用 MDI。所以很明顯,我看不到任何會讓採用曲線變緩的因素;隨著我們往前走、並且有更多資訊被提出,我只看到更陡的採用曲線。

  • - Analyst

    - Analyst

  • Great. One last question. Just as we look at your customer mix, could you give us a ballpark guess on kind of what your self pay mix looks versus those receiving reimbursement from insurance?

    很好。最後一個問題。就你們的客戶組合來看,你能不能大概估一下自費的占比,與由保險給付的占比各是多少?

  • - President, CEO

    - President, CEO

  • Sure. Yes. I can tell you that the latest, I just got this from the sales guys. And a bit ago we were 50/50. We are now probably 65/35 reimbursement versus cash and moving rapidly to more reimbursement less cash.

    當然可以。是的。我可以告訴你最新的——我剛從業務那邊拿到的數字。前一陣子我們是 50/50。現在大概是 65/35:給付 vs. 現金(自費),而且正快速朝向更多給付、較少現金的方向移動。

  • - Analyst

    - Analyst

  • Okay. Great. Thanks for your time, guys.

    好的。很好。謝謝各位撥冗。

  • Operator

    Operator

  • Next we'll take a follow-up question from Bill Plovanic with Canaccord Adams.

    接下來我們接受 Canaccord Adams 的 Bill Plovanic 的追問。

  • - Analyst

    - Analyst

  • Great. Thanks. Just a couple of housekeeping questions. On the first up front payment, the $13 million you are receiving from Edwards, is that going to be amortized quarterly? And if so, how much per quarter?

    很好,謝謝。幾個行政性問題。第一個,Edwards 將支付給你們的 1,300 萬美元前期款,會按季度攤銷嗎?如果會,每季大概是多少?

  • - President, CEO

    - President, CEO

  • No, Bill. We'll get that within 10 days. We signed the agreement today. It is due within 10 days of signing.

    不會,Bill。我們會在 10 天內收到。我們今天簽了協議,款項在簽署後 10 天內到期支付。

  • - Analyst

    - Analyst

  • No but I mean, how -- how long is the agreement for it?

    不,我的意思是,這個協議期限是多久?

  • - President, CEO

    - President, CEO

  • Oh, you are asking how Jess is going to--?

    喔,你是在問 Jess 會怎麼——?

  • - CFO

    - CFO

  • How we're going to account for it, Bill?

    Bill,你是在問我們會怎麼入帳(會計處理)嗎?

  • - Analyst

    - Analyst

  • Yes.

    對。

  • - CFO

    - CFO

  • I think it is similar to what we did with Animas. It is likely the up front fee of the $13 million will be over a period of time that both parties have the rights to update the spec on the product. So we are looking at a two to three-year time period and then we have the development dollars, which we will be, we'll receive in and we'll amortize those on a regular straight line, and then we have the final payments, the milestones that we'll account for at the time of receipt.

    我想會類似我們與 Animas 的做法。這筆 1,300 萬美元的前期費用,很可能會在一段期間內攤提;在該期間內,雙方都有權利更新產品規格。因此我們看的是兩到三年的期間。接著還有研發款項,我們會收到並以固定直線法定期攤銷;最後還有期末付款,也就是里程碑款,我們會在收到時入帳。

  • - Analyst

    - Analyst

  • Okay. So on the up front payment probably three years is a fair assumption to make? Is what you are saying?

    好的。所以前期款以三年作為合理假設可以嗎?你的意思是這樣?

  • - CFO

    - CFO

  • Two to three years, correct.

    兩到三年,沒錯。

  • - Analyst

    - Analyst

  • Okay. And then on the the head count reduction, were there any sales and marketing folks cut with that?

    好的。那麼在人力縮減方面,有裁到任何銷售與行銷人員嗎?

  • - CFO

    - CFO

  • No.

    沒有。

  • - Analyst

    - Analyst

  • So you are still reminded of how many reps you are carrying and where that is today? 25, right?

    所以再提醒一下,你們目前帶著多少位業務代表?現在是 25 位,對嗎?

  • - President, CEO

    - President, CEO

  • Yes, we've got 47 in the field between sales reps and clinical education specialists. Constantly, I think that's a sized appropriately at this point. With where we're at on the reimbursement as, and we watch it. We are overlaying where we are getting better reimbursement over the sales territories. Obviously we don't have the best geographic coverage that I would like. Part of that we need to continue to leverage our partners, in terms of both Animas and potentially other partners in that same skew, but at this point, I don't look to change to size the salesforce any differently.

    是的,我們外勤一共有 47 人,包含業務代表與臨床教育專員。我認為以目前狀況來看,這個規模是合適的。隨著我們在給付上的進展——我們也會持續觀察——我們正在把給付改善的情況疊加到各銷售區域上。很明顯,我們的地理覆蓋並不是我理想中的最佳狀態。部分原因是我們需要持續借力合作夥伴,包括 Animas,以及可能其他具有相同偏向的合作夥伴;但就目前而言,我不打算以不同方式調整銷售團隊的規模。

  • On the marketing side, one of the things that we do need to do, and we are, part of our development is to, and we really haven't had, until Claudia Graham came on board last month, or September now, we didn't really have much of a marketing department to speak of. I think that that's, we just couldn't find the right people. I won't say how long I chased her. But suffice it to say that she was on my radar screen. In any event we need to improve in that particular area with regards to branding and messaging.

    在行銷方面,我們確實需要做的一件事——而且我們正在做——是提升這部分的能力;坦白說,直到 Claudia Graham 上個月加入(現在是九月),我們幾乎稱不上有行銷部門。我想那是因為我們一直找不到合適的人。我不會說我追她追了多久,但可以說她一直在我的雷達上。無論如何,我們需要在品牌與訊息傳遞方面把這一塊做得更好。

  • - Analyst

    - Analyst

  • Okay. Then Jess, the restricted cash on the balance sheet, it went up significantly that is close to $5 million. What, exactly, is that for? And why is that restricted?

    好的。那麼 Jess,資產負債表上的受限制現金大幅增加,接近 500 萬美元。這筆錢確切是用來做什麼的?以及為什麼會被限制使用?

  • - CFO

    - CFO

  • It did. It went up from about $914,000 at year end to over $5 million. What you see now, and that is for the, to secure the equipment lines that we have. We have two equipment lines from one single lender. And as that is repaid, approximately, a little under $200,000 per month, or a little under $600,000 per quarter falls off that restricted cash balance.

    是的。它從年末約 91.4 萬美元增加到超過 500 萬美元。你現在看到的這筆,是用來擔保我們現有的設備融資額度。我們向同一家貸方有兩筆設備融資額度。隨著其償還,大約每月略低於 20 萬美元,或每季略低於 60 萬美元,會從該受限制現金餘額中解除。

  • - Analyst

    - Analyst

  • Okay so it's just coming off of it. Then as we look obviously the capital markets are challenging these days and congratulations on the deal with Edwards. It gives you some more cash in the bank. I mean, just looking at what you started with, and what you have added and what your current burn is, you have probably somewhere at the current burn, even when you start dropping it down a little three to four quarters of cash. What's the strategy at this point to when you get to the end of '09 and into 2010 to bolster the balance sheet?

    了解,所以它會逐步解除。那麼,顯然目前資本市場相當具挑戰性,也恭喜你們與 Edwards 的交易,讓你們帳上多了一些現金。我的意思是,從你們起始的現金、後續增加的現金,以及目前的現金消耗率來看,即使你們開始把消耗率稍微降下來,以目前的消耗速度,你們大概還有三到四個季度的現金。此時此刻的策略是什麼?在 2009 年底到 2010 年之間,打算如何強化資產負債表?

  • - President, CEO

    - President, CEO

  • That's a great question. Obviously we are in constant communication with our Board of Directors on that Bill. And at this point I would have to defer any discussion. The Board has asked us not to comment on that.

    這是個很好的問題。Bill,我們顯然一直與董事會保持密切溝通。不過在這個時間點,我必須暫緩任何相關討論;董事會要求我們不要對此發表評論。

  • - Analyst

    - Analyst

  • All right. Thanks, Terry. I appreciate it.

    好的。謝謝你,Terry。我很感激。

  • - President, CEO

    - President, CEO

  • You bet.

    不客氣。

  • Operator

    Operator

  • We have a follow-up question from Ben Andrew with William Blair.

    我們有來自 William Blair 的 Ben Andrew 的追問。

  • - Analyst

    - Analyst

  • A couple quick things. Terry, maybe talk about the back office staff you have got in terms of if you can, number of people. How well sized is that for patient growth over the next year? And a related question I guess maybe even answer first would be given the backdrop, should we expect patient adds to grow sequentially for a few quarters? Or is it going to take that long before you think it actually starts to get back up to 1000 plus patients per quarter?

    幾個很快的問題。Terry,能否談談你們後勤(back office)人員配置,例如人數?以未來一年病患成長來看,這樣的規模是否合適?另外一個相關問題,或許你可以先回答:在目前的大環境下,我們是否應該預期新增病患數會連續幾個季度逐季成長?還是要等那麼久,你們才會認為它會回升到每季 1,000 名以上的病患?

  • - President, CEO

    - President, CEO

  • Yes. I mean, you are right. I should, I'll answer the second part of the question. First. Certainly over what we did in the third quarter we did 777. I will tell that you we had a far greater number in queue than that number that we processed. I can't describe how many more, but it was significant. I would hope to be able to get, if the last six weeks are any indication of a, at least a bit of a break in the log jam, then I would hope sequentially, Ben, that we are able to do better. But right now, it's too early to really go out on too much of a limb to say that absolutely. I still think it's a couple, two to three quarters away until we completely get it down and get it processed.

    是的。你的判斷沒錯。我先回答問題的第二部分。第三季我們做了 777 名。我可以告訴你,我們排隊等待處理的數量遠高於我們實際處理的這個數字。我無法說多出多少,但幅度很大。如果過去六週能反映出至少有一點點塞車(log jam)緩解的跡象,那麼我希望我們能逐季改善,Ben。但目前還太早,還不宜過度斷言一定會如此。我仍然認為還需要再等幾個季度,大概兩到三個季度,我們才能把它完全消化並處理完。

  • We are not, again we are not lacking. One of my biggest concerns we are working through the backlog now. But we are still getting patients in each and every day. So they are adding to the backlog. Unfortunately we are still not at a point that we are processing them as fast as I would like us to. Some of it is our system. Some of it -- a lot of it is at the third party payer level. Remember we also have to use DME suppliers in cases where we don't have a contract with the particular payer yet, and they do. They are an in network system. So add to that the complexity of taking all of this information that we normally would submit to a payer and actually submitting it to yet a third party, for them then to process with the payer. So, it's pretty complicated right now.

    我們並不是——再次強調,我們並不缺病患。我最大的擔憂之一是我們正在處理積壓案件,但每天仍然有病患進來,所以又會增加積壓。不幸的是,我們仍未達到能以我希望的速度處理的程度。部分原因在於我們的系統;部分原因——很大一部分是在第三方付款方(payer)的層級。請記得,在我們尚未與特定付款方簽約、但 DME 供應商有合約的情況下,我們也必須使用 DME 供應商;他們屬於該付款方的網內(in-network)體系。再加上這個複雜性:我們把原本會提交給付款方的所有資料,改為提交給另一個第三方,讓他們再去與付款方處理。所以目前真的相當複雜。

  • As far -- I don't want to really go into the staffing. Just logistically, I think we are adequately staffed in that particular arena right now. It's a matter of streamlining. We have to become more efficient. And -- than we are today. It is more efficient not only on our side, but also on the receiving end from the payer standpoint that they understand what these packages and they can turn around. Remember who gets these packages, it's a claims adjuster who is looking at a formulary document and saying yea or nay. If they get rejected for any reason whatsoever we go to appeal. Right now it's at the early stages. We are having to work through a very complicated issue right now. Again, given my history, and having gone through this previously in the pump world, it's solvable, it's frustrating, our salesforce is frustrated because they are doing everything we asked them to do. But we are just continuing to force it through the system, if necessary, we do send salesforces into clinics to collect paper, rather than selling. They are not happy with that. But that's what we have to do to clear the log jam periodically we will send them in.

    至於——我不想深入談人力配置。就作業面而言,我認為我們在那個領域目前的人力是足夠的,重點在於流程精簡。我們必須變得更有效率——比現在更有效率。不只是我們這一端要更有效率,付款方那一端的接收端也要更有效率:他們要理解這些資料包(packages),並能快速回覆。請記得,實際收到這些資料包的人,是理賠審核員(claims adjuster),他在看一份給付清單(formulary)文件,然後決定同意或不同意。只要因任何原因被拒絕,我們就會進入申訴(appeal)。目前還在早期階段。我們正在處理一個非常複雜的議題。再次強調,以我的經歷、以及我過去在胰島素幫浦領域的經驗來看,這是可以解決的;它令人沮喪,我們的業務團隊也很沮喪,因為他們已經把我們要求他們做的都做到了。但我們只能持續把案件推進系統;必要時,我們會派業務人員進診所去收集紙本資料,而不是去銷售。他們對此不滿意,但為了定期疏通塞車,我們不得不這麼做,會不時派他們進去。

  • - Analyst

    - Analyst

  • Okay. Thank you.

    好的。謝謝。

  • Operator

    Operator

  • There are no questions in the queue. I will turn the conference over to our host for any closing or additional remarks.

    目前佇列中沒有問題。我將把電話會議交回主持人,請他做任何結語或補充說明。

  • - President, CEO

    - President, CEO

  • Again, thank you for joining us today. Obviously a very exciting time for DexCom. We believe that the partnership with Edwards allows us to take our technology into another particular area of glycemic control that is in reality far greater than our ambulatory world because of the conditions called stress hyperglycemia, in which relatively stable patients have an inability to control their glucose levels and have to be instituted on intensive insulin therapy in order to stabilize them and the resulting outcomes in morbidity and mortality provide us with a unique opportunity. We believe we have the best system. Edwards certainly has looked at all the players in this space and chose us. Because they too believe we have the best system. On the ambulatory side we are making great strides and progress. It's not without its frustrations as we go through this. But the adoption is where we predicted it would be. Maybe even a little north of that. But it's the back office, devils in the details that we are dealing with at this particular point in time. There is a great future ahead of DexCom and thanks again for listening to us and supporting us.

    再次感謝各位今天加入我們。對 DexCom 而言,顯然這是一個非常令人振奮的時刻。我們相信與 Edwards 的合作,讓我們能把技術帶入血糖控制的另一個領域;實際上,這個領域的規模遠大於我們的門診(ambulatory)市場,因為存在一種稱為壓力性高血糖(stress hyperglycemia)的狀況:相對穩定的病患卻無法控制其血糖,必須採取強化胰島素治療(intensive insulin therapy)以使其穩定;而在發病率(morbidity)與死亡率(mortality)方面的結果,為我們提供了獨特的機會。我們相信我們擁有最好的系統。Edwards 當然也檢視了這個領域的所有參與者並選擇了我們,因為他們也相信我們擁有最好的系統。在門診端,我們正取得很大的進展與成果。這個過程並非沒有挫折,但採用速度符合我們的預期,甚至可能略高一些。不過目前我們正在處理的是後勤端——魔鬼藏在細節裡(devils in the details)。DexCom 的未來非常可期,再次感謝各位聆聽並支持我們。

  • Operator

    Operator

  • And that does conclude our conference call. Thank you for joining us today.

    本次電話會議到此結束。感謝各位今天的參與。